Equities Analysts Offer Predictions for VRCA Q4 Earnings

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) – Investment analysts at Brookline Capital Management issued their Q4 2025 earnings per share (EPS) estimates for Verrica Pharmaceuticals in a report issued on Tuesday, March 11th. Brookline Capital Management analyst K. Dolliver forecasts that the company will post earnings per share of ($0.03) for the quarter. The consensus estimate for Verrica Pharmaceuticals’ current full-year earnings is ($1.46) per share.

Separately, Needham & Company LLC reiterated a “hold” rating on shares of Verrica Pharmaceuticals in a research report on Wednesday. Four research analysts have rated the stock with a hold rating and one has given a buy rating to the company. According to MarketBeat.com, Verrica Pharmaceuticals presently has an average rating of “Hold” and an average price target of $9.50.

Verrica Pharmaceuticals Price Performance

VRCA opened at $0.54 on Friday. Verrica Pharmaceuticals has a fifty-two week low of $0.54 and a fifty-two week high of $11.41. The company has a market capitalization of $24.50 million, a P/E ratio of -0.29 and a beta of 1.44. The firm’s fifty day moving average price is $0.68 and its two-hundred day moving average price is $1.11.

Verrica Pharmaceuticals (NASDAQ:VRCA) last announced its quarterly earnings data on Tuesday, March 11th. The company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.01. The company had revenue of $0.34 million for the quarter, compared to analyst estimates of $1.30 million. Verrica Pharmaceuticals had a negative return on equity of 591.84% and a negative net margin of 625.06%.

Institutional Investors Weigh In On Verrica Pharmaceuticals

A number of large investors have recently bought and sold shares of VRCA. Bank of America Corp DE raised its position in Verrica Pharmaceuticals by 347.5% in the 4th quarter. Bank of America Corp DE now owns 143,818 shares of the company’s stock valued at $101,000 after purchasing an additional 111,678 shares during the last quarter. Caligan Partners LP acquired a new stake in shares of Verrica Pharmaceuticals in the fourth quarter valued at $5,201,000. Boothbay Fund Management LLC bought a new position in shares of Verrica Pharmaceuticals in the fourth quarter valued at about $1,811,000. Heights Capital Management Inc. acquired a new position in Verrica Pharmaceuticals during the 4th quarter worth about $246,000. Finally, Renaissance Technologies LLC lifted its position in Verrica Pharmaceuticals by 57.7% during the 4th quarter. Renaissance Technologies LLC now owns 233,300 shares of the company’s stock worth $163,000 after buying an additional 85,336 shares in the last quarter. 42.45% of the stock is currently owned by institutional investors.

Verrica Pharmaceuticals Company Profile

Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.